Kevin Joseph Fitzgerald Sells 2,290 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 2,290 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. This represents a 9.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total value of $547,933.70.
• On Monday, November 17th, Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $359.18 on Friday. The company has a market cap of $47.45 billion, a P/E ratio of 1,496.56 and a beta of 0.32. The firm’s fifty day moving average price is $420.41 and its two-hundred day moving average price is $421.12. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49.

Analyst Ratings Changes

Several equities research analysts have issued reports on ALNY shares. Jefferies Financial Group cut their price objective on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Piper Sandler reissued an “overweight” rating and set a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Raymond James Financial restated an “outperform” rating and issued a $472.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $490.96.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Analysts maintain a generally constructive stance: ALNY carries a consensus “Moderate Buy” from sell‑side firms, supporting a bullish medium‑term view for the shares. Alnylam Pharmaceuticals, Inc. Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Needham published a bullish forecast, highlighting upside tied to Alnylam’s longer‑term (Alnylam 2030) growth plan — a catalyst that could support recovery if execution meets targets. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: Context/valuation pieces are circulating that reassess ALNY’s premium valuation versus the newly unveiled Alnylam 2030 plan — useful for investors weighing long‑range upside against current multiples. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: Analyst opinions are mixed across the healthcare coverage universe, with some firms trimming targets while others remain upbeat — this divergence contributes to higher intraday volatility. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) …
• Negative Sentiment: Concentrated insider selling: multiple senior executives — including CEO Yvonne Greenstreet and several EVPs — disclosed sizable share sales on Jan. 12–13 (individual sales in the $0.5M–$3.5M range), which typically increases near‑term sell pressure and raises investor caution. Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell‑Off
• Negative Sentiment: Market reaction to the company’s ambitious 2026 guidance and the Alnylam 2030 plan was negative — coverage noted a sharp intraday slide after the announcement — and Bank of America issued a pessimistic forecast that may amplify selling pressure. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Bank of America lowered its outlook and flagged downside risk, adding to analyst‑driven selling pressure following the company’s strategic/guidance update. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $25,000. Salomon & Ludwin LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter worth about $27,000. Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals during the third quarter worth about $29,000. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $30,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $32,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.